ET-1拮抗药物治疗肺动脉高压的研究进展

Research Advances in ET-1 Antagonistic Drugs in the Treatment of Pulmonary Hy-pertension

肺动脉高压(PAH)是一种进行性致死性疾病,其特征是肺血流动力学和血管生长调节受损。这些变化会增加肺血管阻力进而引起肺动脉压,导致右心室衰竭,最终结局是死亡。研究证实内皮素-1升高与PAH的发生发展密切相关,针对内皮素通路的靶向药物不仅能改善PAH患者的症状,而且可以延缓甚至逆转疾病进展,改善患者远期预后。本文回顾该领域的相关文献对内皮素拮抗剂PAH中的作用机制、临床应用及未来前景进行综述。

Pulmonary hypertension (PAH) is a progressive, lethal disease characterized by impaired pulmo-nary hemodynamics and vascular growth regulation. These changes increase pulmonary vascular resistance, which in turn causes pulmonary artery pressure, leading to right ventricular failure, with the end resulting in death. Studies have confirmed that elevated endothelin-1 is closely related to the development of PAH, and targeted drugs targeting the endothelin pathway can not only im-prove symptoms in patients with PAH, but also delay or even reverse disease progression and im-prove long-term prognosis for patients. This paper reviews the literature in this field to review the mechanism of action, clinical application and future prospects of the endothelin antagonist PAH.